Influence of CYP2C19 genotype on the pharmacokinetics of R483, a CYP2C19 substrate, in healthy subjects and type 2 diabetes patients
R483 is a thiazolidinedione peroxisome proliferator-activated receptor gamma (PPAR gamma) agonist with anti-diabetic properties and also a cytochrome P450 2C19 (CYP2C19) substrate. The aim of the clinical studies reported here was to investigate the influence of the CYP2C19 genotype on the pharmacok...
Saved in:
Main Authors: | Bogman, K., Silkey, M., Chan, S.P., Tomlinson, B., Weber, C. |
---|---|
Format: | Article |
Published: |
Springer Verlag (Germany)
2010
|
Subjects: | |
Online Access: | http://eprints.um.edu.my/12236/ |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Population Pharmacokinetics Of Repaglinide In
Healthy Subjects And Genetic Polymorphisms Of
Cyp3a4 And Cyp2c8
by: Abu Bakar, Ruzilawati
Published: (2008) -
A minireview of CYP2C9 AND CYP2C19 Single Nucleotide Polymorphisms (SNPs) among Malaysian populations
by: Rusli, Ismail, et al.
Published: (2017) -
Genotyping of CYP2C9 for cardiovascular patients / Norshazareen Abd Manab
by: Abd Manab, Norshazareen
Published: (2005) -
Genetic polymorphisms of CYP 3A4 & CYP2C8 in healthy volunteers title of project administered with repaglinide
by: Hua, Gan Siew
Published: (2008) -
CYP2C9 polymorphism: prevalence in healthy and warfarin-treated Malay and Chinese in Malaysia
by: Ngow, Harris Abdullah, et al.
Published: (2009)